PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsCastration-resistant prostatic neoplasms
MeSH D064129 - castration-resistant prostatic neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D011471:Prostatic neoplasms
$
Success rate
D064129: 
Castration-resistant prostatic neoplasms
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaAbiraterone Abiraterone  2018-10-31   
Glenmark PharmaceuticalsAbiraterone Abiraterone  2019-10-16   
MylanAbiraterone Abiraterone  2018-10-31   
Abiraterone Abiraterone Mylan  2021-08-20   
Johnson & JohnsonAbiraterone Zytiga  2011-04-28 $695 M Q4/23-Q3/24 
Niraparib, Abiraterone Akeega 2027-08-12 2023-08-11   
NovartisLutetium (177lu) vipivotide tetraxetan Pluvicto  2022-12-09 $595 M Q2/22-Q2/24 
BayerDarolutamide Nubeqa  2020-03-27   
Dr Reddys LaboratoriesAbiraterone Abiraterone  2020-05-18   
Rising PharmaceuticalsAbiraterone Abiraterone  2019-02-25   
Sun Pharmaceutical IndustriesAbiraterone Yonsa 2034-03-17 2018-05-22   
ApotexAbiraterone Abiraterone  2018-10-31   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
52%
68/132
Phase 2
27%
31/116
Phase 3
32%
12/37
Approved: 3Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use